{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T18:59:33Z","timestamp":1759777173261},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"22","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>BCR-ABL tyrosine kinase inhibitors (TKI) have dramatically improved therapy for chronic myelogenous leukemia (CML). However, several problems leading to TKI resistance still impede a complete cure of this disease. IFN regulatory factor-8 (IRF8) is a transcription factor essential for the development and functions of immune cells, including dendritic cells. Irf8\u2212\/\u2212 mice develop a CML-like disease and IRF8 expression is downregulated in patients with CML, suggesting that IRF8 is involved in the pathogenesis of CML. In this study, by using a murine CML model, we show that BCR-ABL strongly inhibits a generation of dendritic cells from an early stage of their differentiation in vivo, concomitant with suppression of Irf8 expression. Forced expression of IRF8 overrode BCR-ABL (both wild-type and T315I-mutated) to rescue dendritic cell development in vitro, indicating that the suppression of Irf8 causes dendritic cell deficiency. Gene expression profiling revealed that IRF8 restored the expression of a significant portion of BCR-ABL\u2013dysregulated genes and predicted that BCR-ABL has immune-stimulatory potential. Indeed, IRF8-rescued BCR-ABL\u2013expressing dendritic cells were capable of inducing CTLs more efficiently than control dendritic cells. Altogether, our findings suggest that IRF8 is an attractive target in next-generation therapies for CML. Cancer Res; 73(22); 6642\u201353. \u00a92013 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-13-0802","type":"journal-article","created":{"date-parts":[[2013,11,15]],"date-time":"2013-11-15T05:47:07Z","timestamp":1384494427000},"page":"6642-6653","update-policy":"http:\/\/dx.doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Transcription Factor IRF8 Counteracts BCR-ABL to Rescue Dendritic Cell Development in Chronic Myelogenous Leukemia"],"prefix":"10.1158","volume":"73","author":[{"given":"Tomoya","family":"Watanabe","sequence":"first","affiliation":[{"name":"Authors' Affiliations: Departments of 1Immunology, 2Environmental Immuno-Dermatology, 3Internal Medicine and Clinical Immunology, and 4Experimental Animal Science, Yokohama City University Graduate School of Medicine; and 5Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan"},{"name":"Authors' Affiliations: Departments of 1Immunology, 2Environmental Immuno-Dermatology, 3Internal Medicine and Clinical Immunology, and 4Experimental Animal Science, Yokohama City University Graduate School of Medicine; and 5Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chie","family":"Hotta","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Immunology, 2Environmental Immuno-Dermatology, 3Internal Medicine and Clinical Immunology, and 4Experimental Animal Science, Yokohama City University Graduate School of Medicine; and 5Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichi","family":"Koizumi","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Immunology, 2Environmental Immuno-Dermatology, 3Internal Medicine and Clinical Immunology, and 4Experimental Animal Science, Yokohama City University Graduate School of Medicine; and 5Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuho","family":"Miyashita","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Immunology, 2Environmental Immuno-Dermatology, 3Internal Medicine and Clinical Immunology, and 4Experimental Animal Science, Yokohama City University Graduate School of Medicine; and 5Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan"},{"name":"Authors' Affiliations: Departments of 1Immunology, 2Environmental Immuno-Dermatology, 3Internal Medicine and Clinical Immunology, and 4Experimental Animal Science, Yokohama City University Graduate School of Medicine; and 5Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Nakabayashi","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Immunology, 2Environmental Immuno-Dermatology, 3Internal Medicine and Clinical Immunology, and 4Experimental Animal Science, Yokohama City University Graduate School of Medicine; and 5Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Kurotaki","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Immunology, 2Environmental Immuno-Dermatology, 3Internal Medicine and Clinical Immunology, and 4Experimental Animal Science, Yokohama City University Graduate School of Medicine; and 5Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Go R.","family":"Sato","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Immunology, 2Environmental Immuno-Dermatology, 3Internal Medicine and Clinical Immunology, and 4Experimental Animal Science, Yokohama City University Graduate School of Medicine; and 5Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Immunology, 2Environmental Immuno-Dermatology, 3Internal Medicine and Clinical Immunology, and 4Experimental Animal Science, Yokohama City University Graduate School of Medicine; and 5Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Nakazawa","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Immunology, 2Environmental Immuno-Dermatology, 3Internal Medicine and Clinical Immunology, and 4Experimental Animal Science, Yokohama City University Graduate School of Medicine; and 5Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Fujita","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Immunology, 2Environmental Immuno-Dermatology, 3Internal Medicine and Clinical Immunology, and 4Experimental Animal Science, Yokohama City University Graduate School of Medicine; and 5Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rika","family":"Sakai","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Immunology, 2Environmental Immuno-Dermatology, 3Internal Medicine and Clinical Immunology, and 4Experimental Animal Science, Yokohama City University Graduate School of Medicine; and 5Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Fujisawa","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Immunology, 2Environmental Immuno-Dermatology, 3Internal Medicine and Clinical Immunology, and 4Experimental Animal Science, Yokohama City University Graduate School of Medicine; and 5Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Nishiyama","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Immunology, 2Environmental Immuno-Dermatology, 3Internal Medicine and Clinical Immunology, and 4Experimental Animal Science, Yokohama City University Graduate School of Medicine; and 5Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zenro","family":"Ikezawa","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Immunology, 2Environmental Immuno-Dermatology, 3Internal Medicine and Clinical Immunology, and 4Experimental Animal Science, Yokohama City University Graduate School of Medicine; and 5Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Aihara","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Immunology, 2Environmental Immuno-Dermatology, 3Internal Medicine and Clinical Immunology, and 4Experimental Animal Science, Yokohama City University Graduate School of Medicine; and 5Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Ishigatsubo","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Immunology, 2Environmental Immuno-Dermatology, 3Internal Medicine and Clinical Immunology, and 4Experimental Animal Science, Yokohama City University Graduate School of Medicine; and 5Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiko","family":"Tamura","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Immunology, 2Environmental Immuno-Dermatology, 3Internal Medicine and Clinical Immunology, and 4Experimental Animal Science, Yokohama City University Graduate School of Medicine; and 5Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2013,11,14]]},"reference":[{"key":"2022061703523518000_bib1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"key":"2022061703523518000_bib2","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/ajh.23282","article-title":"Chronic myeloid leukemia: 2012 Update on diagnosis, monitoring, and management","volume":"87","author":"Jabbour","year":"2012","journal-title":"Am J Hematol"},{"key":"2022061703523518000_bib3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev.immunol.22.012703.104753","article-title":"The BCR-ABL story: bench to bedside and back","volume":"22","author":"Wong","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"2022061703523518000_bib4","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia","volume":"12","author":"O'Hare","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"2022061703523518000_bib5","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1634\/stemcells.2005-0069","article-title":"Effects of imatinib on normal hematopoiesis and immune activation","volume":"23","author":"Appel","year":"2005","journal-title":"Stem Cells"},{"key":"2022061703523518000_bib6","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.2174\/092986711798184271","article-title":"Effects of BCR-ABL inhibitors on anti-tumor immunity","volume":"18","author":"Krusch","year":"2011","journal-title":"Curr Med Chem"},{"key":"2022061703523518000_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/eji.201242699","article-title":"The tyrosine kinase inhibitor dasatinib suppresses cytokine production by plasmacytoid dendritic cells by targeting endosomal transport of CpG DNA","volume":"43","author":"Fujita","year":"2013","journal-title":"Eur J Immunol"},{"key":"2022061703523518000_bib8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nature06175","article-title":"Taking dendritic cells into medicine","volume":"449","author":"Steinman","year":"2007","journal-title":"Nature"},{"key":"2022061703523518000_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.0105-2896.2009.00879.x","article-title":"Origin and development of dendritic cells","volume":"234","author":"Liu","year":"2010","journal-title":"Immunol Rev"},{"key":"2022061703523518000_bib10","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/79526","article-title":"Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia","volume":"6","author":"Molldrem","year":"2000","journal-title":"Nat Med"},{"key":"2022061703523518000_bib11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood-2002-02-0659","article-title":"Interferon-\u03b1, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia","volume":"101","author":"Burchert","year":"2003","journal-title":"Blood"},{"key":"2022061703523518000_bib12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/(SICI)1096-8652(199701)54:1<61::AID-AJH9>3.0.CO;2-2","article-title":"Chronic myeloid leukemia as an immunological target","volume":"54","author":"Lim","year":"1997","journal-title":"Am J Hematol"},{"key":"2022061703523518000_bib13","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood"},{"key":"2022061703523518000_bib14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1046\/j.1365-2141.2002.03831.x","article-title":"Low blood dendritic cells in chronic myeloid leukaemia patients correlates with loss of CD34+\/CD38\u2212 primitive haematopoietic progenitors","volume":"119","author":"Mohty","year":"2002","journal-title":"Br J Haematol"},{"key":"2022061703523518000_bib15","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1038\/sj.leu.2403474","article-title":"Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate","volume":"18","author":"Boissel","year":"2004","journal-title":"Leukemia"},{"key":"2022061703523518000_bib16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1365-2141.2003.03979.x","article-title":"Phenotypic and functional deficiencies of leukaemic dendritic cells from patients with chronic myeloid leukaemia","volume":"120","author":"Eisendle","year":"2003","journal-title":"Br J Haematol"},{"key":"2022061703523518000_bib17","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1182\/blood-2002-06-1841","article-title":"Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration","volume":"101","author":"Dong","year":"2003","journal-title":"Blood"},{"key":"2022061703523518000_bib18","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1182\/blood-2008-05-156471","article-title":"Defective homing and impaired induction of cytotoxic T cells by BCR\/ABL-expressing dendritic cells","volume":"113","author":"Mumprecht","year":"2009","journal-title":"Blood"},{"key":"2022061703523518000_bib19","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1146\/annurev.immunol.26.021607.090400","article-title":"The IRF family transcription factors in immunity and oncogenesis","volume":"26","author":"Tamura","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"2022061703523518000_bib20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/blood-2002-04-1088","article-title":"Essential role for ICSBP in the in vivo development of murine CD8\u03b1+ dendritic cells","volume":"101","author":"Aliberti","year":"2003","journal-title":"Blood"},{"key":"2022061703523518000_bib21","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.4049\/jimmunol.174.5.2573","article-title":"IFN regulatory factor-4 and -8 govern dendritic cell subset development and their functional diversity","volume":"174","author":"Tamura","year":"2005","journal-title":"J Immunol"},{"key":"2022061703523518000_bib22","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1084\/jem.20021263","article-title":"ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8\u03b1(+) dendritic cells","volume":"196","author":"Schiavoni","year":"2002","journal-title":"J Exp Med"},{"key":"2022061703523518000_bib23","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1182\/blood-2012-06-437863","article-title":"Essential role of the IRF8-KLF4 transcription factor cascade in murine monocyte differentiation","volume":"121","author":"Kurotaki","year":"2013","journal-title":"Blood"},{"key":"2022061703523518000_bib24","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1074-7613(00)00016-9","article-title":"ICSBP directs bipotential myeloid progenitor cells to differentiate into mature macrophages","volume":"13","author":"Tamura","year":"2000","journal-title":"Immunity"},{"key":"2022061703523518000_bib25","doi-asserted-by":"crossref","first-page":"12123","DOI":"10.1073\/pnas.1201453109","article-title":"Interferon regulatory factor 8 integrates T-cell receptor and cytokine-signaling pathways and drives effector differentiation of CD8 T cells","volume":"109","author":"Miyagawa","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061703523518000_bib26","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0092-8674(00)81348-3","article-title":"Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene","volume":"87","author":"Holtschke","year":"1996","journal-title":"Cell"},{"key":"2022061703523518000_bib27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa1100066","article-title":"IRF8 mutations and human dendritic-cell immunodeficiency","volume":"365","author":"Hambleton","year":"2011","journal-title":"N Engl J Med"},{"key":"2022061703523518000_bib28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.V91.1.22","article-title":"Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias","volume":"91","author":"Schmidt","year":"1998","journal-title":"Blood"},{"key":"2022061703523518000_bib29","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1182\/blood.V97.11.3648","article-title":"Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha","volume":"97","author":"Schmidt","year":"2001","journal-title":"Blood"},{"key":"2022061703523518000_bib30","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1182\/blood-2003-01-0291","article-title":"ICSBP\/IRF-8 inhibits mitogenic activity of p210 Bcr\/Abl in differentiating myeloid progenitor cells","volume":"102","author":"Tamura","year":"2003","journal-title":"Blood"},{"key":"2022061703523518000_bib31","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1128\/MCB.20.4.1149-1161.2000","article-title":"Expression of interferon consensus sequence binding protein (ICSBP) Is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder","volume":"20","author":"Hao","year":"2000","journal-title":"Mol Cell Biol"},{"key":"2022061703523518000_bib32","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1182\/blood.V97.11.3491","article-title":"Expression of interferon consensus sequence binding protein induces potent immunity against BCR\/ABL-induced leukemia","volume":"97","author":"Deng","year":"2001","journal-title":"Blood"},{"key":"2022061703523518000_bib33","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1182\/blood-2008-07-167189","article-title":"ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines","volume":"113","author":"Nardi","year":"2009","journal-title":"Blood"},{"key":"2022061703523518000_bib34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2220\/biomedres.32.159","article-title":"One-step simple assay to determine antigen-specific cytotoxic activities by single-color flow cytometry","volume":"32","author":"Nakagawa","year":"2011","journal-title":"Biomed Res"},{"key":"2022061703523518000_bib35","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1126\/science.1178331","article-title":"Development of monocytes, macrophages, and dendritic cells","volume":"327","author":"Geissmann","year":"2010","journal-title":"Science"},{"key":"2022061703523518000_bib36","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061703523518000_bib37","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/ni.2370","article-title":"Deciphering the transcriptional network of the dendritic cell lineage","volume":"13","author":"Miller","year":"2012","journal-title":"Nat Immunol"},{"key":"2022061703523518000_bib38","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/intimm\/dxf082","article-title":"Global reprogramming of dendritic cells in response to a concerted action of inflammatory mediators","volume":"14","author":"Lindstedt","year":"2002","journal-title":"Int Immunol"},{"key":"2022061703523518000_bib39","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nri2545","article-title":"Immunogenic and tolerogenic cell death","volume":"9","author":"Green","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"2022061703523518000_bib40","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1128\/MCB.15.10.5258","article-title":"Regulation of interleukin 12 p40 expression through an NF-\u03baB half-site","volume":"15","author":"Murphy","year":"1995","journal-title":"Mol Cell Biol"},{"key":"2022061703523518000_bib41","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.1164206","article-title":"Batf3 deficiency reveals a critical role for CD8\u03b1+ dendritic cells in cytotoxic T cell immunity","volume":"322","author":"Hildner","year":"2008","journal-title":"Science"},{"key":"2022061703523518000_bib42","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1084\/jem.20101159","article-title":"Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8\u03b1+ dendritic cells","volume":"208","author":"Fuertes","year":"2011","journal-title":"J Exp Med"},{"key":"2022061703523518000_bib43","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1084\/jem.20101158","article-title":"Type I interferon is selectively required by dendritic cells for immune rejection of tumors","volume":"208","author":"Diamond","year":"2011","journal-title":"J Exp Med"},{"key":"2022061703523518000_bib44","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1182\/blood-2003-08-2970","article-title":"Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR\/ABL and down-regulates bcl-2","volume":"103","author":"Burchert","year":"2004","journal-title":"Blood"},{"key":"2022061703523518000_bib45","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/leu.2009.74","article-title":"BCR-ABL promotes neutrophil differentiation in the chronic phase of chronic myeloid leukemia by downregulating c-Jun expression","volume":"23","author":"Kobayashi","year":"2009","journal-title":"Leukemia"},{"key":"2022061703523518000_bib46","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2011-06-364976","article-title":"IRF-8 extinguishes neutrophil production and promotes dendritic cell lineage commitment in both myeloid and lymphoid mouse progenitors","volume":"119","author":"Becker","year":"2012","journal-title":"Blood"},{"key":"2022061703523518000_bib47","doi-asserted-by":"crossref","first-page":"8705","DOI":"10.1073\/pnas.96.15.8705","article-title":"Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1","volume":"96","author":"Zhang","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061703523518000_bib48","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00251-010-0444-1","article-title":"Suppressive effects of transcription factor GATA-1 on cell type-specific gene expression in dendritic cells","volume":"62","author":"Shimokawa","year":"2010","journal-title":"Immunogenetics"},{"key":"2022061703523518000_bib49","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood-2005-06-2516","article-title":"Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase\/AKT signaling pathway","volume":"107","author":"Zhao","year":"2006","journal-title":"Blood"},{"key":"2022061703523518000_bib50","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.immuni.2008.02.013","article-title":"The signal transducer STAT5 inhibits plasmacytoid dendritic cell development by suppressing transcription factor IRF8","volume":"28","author":"Esashi","year":"2008","journal-title":"Immunity"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/73\/22\/6642\/2690352\/6642.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/73\/22\/6642\/2690352\/6642.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T13:23:28Z","timestamp":1655472208000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/73\/22\/6642\/584807\/The-Transcription-Factor-IRF8-Counteracts-BCR-ABL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,14]]},"references-count":50,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2013,11,14]]},"published-print":{"date-parts":[[2013,11,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-13-0802","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,14]]}}}